Clinical Trial Detail

NCT ID NCT02732938
Title Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Pfizer
Indications

pancreatic ductal adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel + PF-04136309

Age Groups: adult

No variant requirements are available.